DIMOCO Notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents
1.10.2020 14:05:00 EEST | Business Wire | Press release
Since January 2018, mobile network operators (MNOs) are obliged to operate under the telecommunication exemption of PSD2 regulation, entitling them to only process digital goods, ticketing, parking and charities, but restricts them to extend the billing of goods and services outside the telecommunication exemption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005598/en/
DIMOCO Presse Release: DIMOCO notifies German Mobile Network Operators Telefónica Germany, Telekom and Vodafone as Payment Agents (Graphic: Business Wire)
The DIMOCO agent model enables MNOs to operate under the company’s financial license, enabling them to process payments for goods and services outside this exemption.
DIMOCO, a leading provider for direct MNO connections in Europe, currently obtains 210 MNO connections in 48 countries, covering 90 percent of Europe. Since 2016, DIMOCO operates under its payment license, granted by the Austrian Financial Market Authority (FMA) and passported into all EU member states. Consequently, DIMOCO can process transactions for goods and services outside the telecommunication exemption of PSD2 under its licence for MNOs who have been notified as DIMOCO agents.
"Obtaining an own license has been a route that most of the MNOs haven’t pursued as it's a very complex and costly procedure. Being notified as a DIMOCO agent is not only much faster and easier, MNOs can also benefit from our expertise and experience as a licensed payment institute," explains Clemens Leitner, Executive Vice President, Carrier & Business Development at DIMOCO Carrier Billing. "We are all set to deploy DCB payments for carsharing, taxis, rental of e-scooters, electric car charging and many other industries, emphasizing on a solid legal basis."
The German MNOs Telefónica Germany, Telekom and Vodafone have been the first to recognize the immense potential of the agent model partnership with DIMOCO and the vast market possibilities under this model. Out of a German population of currently 83.02 million inhabitants only 40 million people own a credit card and 23 million hold a PayPal account. In 2019, over 140 million mobile subscriptions were registered in Germany, ranking carrier billing as the payment method with the highest penetration and subsequently widest reach, available to more potential customers than any other payment method.
About DIMOCO
DIMOCO Carrier Billing is a European-wide regulated payment institute for Direct Carrier Billing and holds a payment service license from the Austrian Financial Market Authority (FMA), passported to all EU member states.
As a trusted partner of mobile network operators, it enables over one billion subscribers to purchase goods and services from merchants and aggregators with their mobile devices, charged via the operators’ billing system.
Website: dimoco.eu/carrierbilling
Twitter: @Dimoco
LinkedIn: @DIMOCO Carrier Billing
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005598/en/
Contact information
More information
Picture material
High resolution
Low resolution
@DIMOCO
Press contact
DIMOCO Corporate Headquarters
Charlotte Newby
+43 1 33 66 888 – 2059
c.newby@dimoco.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom